Login
Login     |     Register     |     Recover Username/Password

General Investing

Horizon Technology Finance Corp. (HRZN) Diversifies Investments and Trades Below NAV

December 20, 2012

Horizon Technology Finance Corp. (HRZN) recently began trading at a discount to net asset value, creating an entry point into the BDC space for investors, says Casey Alexander, Senior Vice President at Gilford Securities Incorporated. HRZN is a venture-debt business, and the company invests in businesses that have already attracted capital from investors like IBM Ventures and Kleiner Perkins.

“We are actively helping investors accumulate a position in Horizon Technology Finance as we speak. We’re talking to investors on a regular basis about increasing their exposure to Horizon Technology Finance because we believe that at the current price with a yield, a current yield of 10%, that when it hopefully repeats its history and trades back towards net asset value in excess of $16 that we will receive the 12% current yield and 12% to 15% appreciation, thus giving us a total return of something between 20% and 30%, an above-average total rate of return for our investors,” Alexander said.

Horizon Technology Finance provides a little slice of debt on the back end of venture capital deals that involve large capital investors for working capital, says Alexander, which in his opinion partially protects the investment since there are large amounts by the likes of IMB Ventures and Kleiner Perkins. The deals are more diversified too, he says.

“In a business development company with a market cap of $140 million or so, their deals are cut into 4, 5, 6, 7 million dollar slices. Also, venture debt deals tend to amortize or pay down faster than the average business development company middle-market deal does, so the overall risk exposure to each loan declines fairly quickly over the life of the loan, which in general is only four to five years to begin with,” Alexander said.


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now